What current biopharma leaders have the potential to “transcend” beyond this industry? Chief Editor Rob Wright gives his top three choices.
Is the pharma industry ready to move beyond the buzz regarding terms like terms like AI, digital health, and machine learning (ML)?
Ameet Nathwani, M.D., EVP of medical function at Sanofi, gives the inside scoop on what’s required when it comes to preparing a Big Pharma to be digital-health ready.
A summary from the BIO conference panel “Don’t Be Foreign To Foreign Affairs — How To Broker Biopharma Strategic Alliances And Partnerships Between International Stakeholders”
A primer on AI terminology for the upcoming August feature with Sanofi’s Medical Function EVP, Ameet Nathwani, M.D.
An op-ed regarding Pfizer’s drug-pricing actions, President Trump, and the potential impact on the biopharmaceutical industry’s image.
A review of buzzwords and phrases that should be used less in the world of business.
Tom Wiggans, founder, chairman, and CEO of Dermira, provides an overview of the dermatology market, the impetus for founding Dermira, and transparently shares his experience regarding his company’s Phase 3 clinical trial failures.
Jeff Jonas, M.D., CEO of Sage Therapeutics, discusses how the company is preparing to launch a new CNS product likely to change the paradigm for how postpartum depression is treated.